Latest Technology News

Genetic Technologies Limited remains under voluntary administration while progressing a Deed of Company Arrangement and has completed the sale of its geneType business, ending the quarter with $270,000 in cash.

Kjerulf David Hastings Ainsworth has issued a first supplementary statement for his second off-market takeover bid targeting 5.5% of Ainsworth Game Technology shares at $1.30 each, revealing an 8.24% voting stake ahead of the offer’s close.

Blue Star Helium has successfully raised A$10 million through an oversubscribed placement, positioning itself to accelerate production at its Galactica and Pegasus helium projects.

State Gas Limited has decided against proceeding with the sale of its High Density Natural Gas Pilot Plant after failing to finalise terms, while its R&D tax incentive claim remains under extended review by the ATO.

Aldoro Resources has reported a significant 50% increase in rare earth and strontium grades across a 525-meter continuous mineralised interval at its Kameelburg deposit in Namibia, reinforcing the project's scale and potential.

Atomo Diagnostics stands to gain significantly as Lumos Diagnostics’ FebriDx test secures FDA CLIA waiver approval, vastly expanding its US market potential. This regulatory milestone triggers substantial contracted revenues and prompts Atomo to ramp up production.

Impact Minerals has raised A$2 million through a strategic placement to advance its High Purity Alumina project and explore new industrial minerals opportunities in Western Australia.

Aroa Biosurgery has completed its Symphony randomised controlled trial, demonstrating improved healing rates for diabetic foot ulcers compared to standard care. The preliminary results pave the way for clinical adoption and potential US reimbursement.

Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.

EML Payments has appointed Adam Olding as its Global CEO, marking a pivotal step in its EML 2.0 transformation and signalling strengthened leadership to drive growth. Concurrently, regulatory developments around its Australian banking licence application introduce new compliance dynamics.

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

Barton Gold Holdings has secured a $520,000 cash refund through the Federal Government’s R&D Tax Incentive, bolstering its exploration efforts in South Australia’s emerging gold province.